

Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mr. ASHOK OBEROI	PATIENT ID	: 1779172
AGE/ GENDER	: 71 YRS/MALE	REG. NO./LAB NO.	: 012503050013
COLLECTED BY	:	REGISTRATION DATE	: 05/Mar/2025 09:19 AM
REFERRED BY	:	COLLECTION DATE	: 05/Mar/2025 09:22AM
BARCODE NO.	: 01526487	REPORTING DATE	: 05/Mar/2025 11:06AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

CLINICAL CHEMISTRY/BIOCHEMISTRY

LIPID PROFILE : BASIC

CHOLESTEROL TOTAL: SERUM <i>by CHOLESTEROL OXIDASE PAP</i>	63.55	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0
TRIGLYCERIDES: SERUM <i>by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)</i>	115.6	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTEROL (DIRECT): SERUM <i>by SELECTIVE INHIBITION</i>	15.26 ^L	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTEROL: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	25.17	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLESTEROL: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	48.29	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTEROL: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	23.12	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	242.7 ^L	mg/dL	350.00 - 700.00
CHOLESTEROL/HDL RATIO: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	4.16	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0




 DR. VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


 DR. YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mr. ASHOK OBEROI	PATIENT ID	: 1779172
AGE/ GENDER	: 71 YRS/MALE	REG. NO./LAB NO.	: 012503050013
COLLECTED BY	:	REGISTRATION DATE	: 05/Mar/2025 09:19 AM
REFERRED BY	:	COLLECTION DATE	: 05/Mar/2025 09:22AM
BARCODE NO.	: 01526487	REPORTING DATE	: 05/Mar/2025 11:06AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
LDL/HDL RATIO: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	1.65	RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	7.58 ^H	RATIO	3.00 - 5.00

INTERPRETATION:

- Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.
- As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogenic lipoproteins such as LDL, VLDL, IDL, Lp(a), Chylomicron remnants) along with LDL-cholesterol as co-primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL.
- Additional testing for Apolipoprotein B, hsCRP, Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement




 DR. VINAY CHOPRA

CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


 DR. YUGAM CHOPRA

CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mr. ASHOK OBEROI	PATIENT ID	: 1779172
AGE/ GENDER	: 71 YRS/MALE	REG. NO./LAB NO.	: 012503050013
COLLECTED BY	:	REGISTRATION DATE	: 05/Mar/2025 09:19 AM
REFERRED BY	:	COLLECTION DATE	: 05/Mar/2025 09:22AM
BARCODE NO.	: 01526487	REPORTING DATE	: 05/Mar/2025 11:06AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

CREATININE

CREATININE: SERUM by ENZYMATIC, SPECTROPHOTOMETRY	1.15	mg/dL	0.40 - 1.40
--	------	-------	-------------




 DR.VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


 DR.YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mr. ASHOK OBEROI	PATIENT ID	: 1779172
AGE/ GENDER	: 71 YRS/MALE	REG. NO./LAB NO.	: 012503050013
COLLECTED BY	:	REGISTRATION DATE	: 05/Mar/2025 09:19 AM
REFERRED BY	:	COLLECTION DATE	: 05/Mar/2025 09:22AM
BARCODE NO.	: 01526487	REPORTING DATE	: 06/Mar/2025 11:02AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

VALPROATE/VALPORIC ACID

SERUM VALPROATE/VALPROIC ACID by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)	89.3	µg/mL	50 - 100
--	------	-------	----------

INTERPRETATION:

RESULT IN µg/mL	REMARKS
50	Minimum effective concentration
50 - 100	Therapeutic range
>100	Toxic range

NOTE:

1. Trough level is ideal for monitoring blood concentration
2. In Uremia, Cirrhosis or concurrent drug therapy the percent of free Valproic acid increases

COMMENTS:

Valproic acid is used for the treatment of Absence seizures. It is also useful against Tonicclonic & Partial seizures when used in conjunction with other Antiepileptic agents. Single dose half life in healthy adults is 16 hours which decreases to 12 hours on chronic therapy and maybe as short as 8 hours in children. In neonates and hepatic disease when metabolism is reduced, half life becomes prolonged. Peak concentrations occur 1-4 hours after an oral dose. Dosing is problematic in young children who might sleep for more than one complete half life of the drug

*** End Of Report ***



Dr. Vinay Chopra

DR. VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

Dr. Yugam Chopra

DR. YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)

